In 2017, the US Food and Drug Administration approved the BRAF TKI dabrafenib and the MEK inhibitor trametinib as a combination therapy for metastatic NSCLC patients with BRAF V600E mutation, following response rates of 61% in a phase 2 clinical trial [44]. Here, BRAF is linked to non-small cell lung carcinoma.